Clinical Trials Directory

Trials / Completed

CompletedNCT06854107

Intratumoral and Peritumoral Habitat Radiomics of MRI Predict Pathologic Complete Response to Neoadjuvant Chemoimmunotherapy in Oral Squamous Cell Carcinoma

Status
Completed
Phase
Study type
Observational
Enrollment
225 (actual)
Sponsor
Zilong Yuan · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Background:Neoadjuvant chemoimmunotherapy (NACI) shows promise in oral squamous cell carcinoma (OSCC), but reliable noninvasive biomarkers for predicting pathologic complete response (pCR) remain scarce. Radiomics integrating intratumoral and peritumoral heterogeneity across multi-sequence MRI may offer novel insights into treatment response evaluation. Methods: The data of 212 patients with OSCC after NACI were retrospectively collected and analyzed. Among these patients, 56 (26.4%) achieved pCR after NACI. Intratumoral and peritumoral habitat imaging (HI) was achieved using the K-means clustering algorithm applied to T1-weighted imaging (T1WI), axial T2-weighted imaging with fat suppression (T2WI), and contrast-enhanced T1-weighted imaging with fat suppression (T1C). Moreover, intratumoral and peritumoral HI models were constructed and compared using the receiver operating characteristic (ROC) curve. Five-fold cross-validation was performed to mitigate model overfitting.

Conditions

Timeline

Start date
2023-12-01
Primary completion
2023-12-01
Completion
2023-12-01
First posted
2025-03-03
Last updated
2025-03-06

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06854107. Inclusion in this directory is not an endorsement.

Intratumoral and Peritumoral Habitat Radiomics of MRI Predict Pathologic Complete Response to Neoadjuvant Chemoimmunothe (NCT06854107) · Clinical Trials Directory